What question did this study set out to answer?

This research aims to explore the use of antisense oligonucleotide (ASO) therapy to selectively inhibit JAK2 in hematological malignancies with JAK2 V617F mutations.

December 8, 2025Blood

Selective ASO-based JAK2 inhibitor for the treatment of hematological malignancies with JAK2 V617F mutation burden

View Full Paper

Ask AI

Bookmark

Authors

BPBart Przychodzen SSSandra Smieszek

Discussion

Member takes

Overview

Preclinical findings demonstrate that ASO treatment decreases JAK2 levels in hematological malignancies, suggesting a potential targeted therapy.

Key Points

This research aims to explore the use of antisense oligonucleotide (ASO) therapy to selectively inhibit JAK2 in hematological malignancies with JAK2 V617F mutations.
Utilized 19mer ASOs targeting JAK2 coding sequence
Performed qPCR and Western blot analyses on HEL and SET2 cell lines
Evaluated PBMCs from PV patients in methylcellulose cultures with ASO treatment
Demonstrated ~50% reduction of JAK2 transcript in HEL cells after ASO treatment
Observed ~70% decrease in JAK2 protein levels in ASO-treated cells
Noted a 35% reduction in phosphorylated STAT5 levels after treatment
Reduced erythroid colony formation in PV PBMCs post-ASO treatment

Cite This Study

Przychodzen et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d215 https://doi.org/10.1182/blood-2025-7283

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

Selective ASO-based JAK2 inhibitor for the treatment of hematological malignancies with JAK2 V617F mutation burden

View Full Paper

Ask AI

Bookmark

Authors

BPBart Przychodzen SSSandra Smieszek

Discussion

Member takes

Overview

Preclinical findings demonstrate that ASO treatment decreases JAK2 levels in hematological malignancies, suggesting a potential targeted therapy.

Key Points

This research aims to explore the use of antisense oligonucleotide (ASO) therapy to selectively inhibit JAK2 in hematological malignancies with JAK2 V617F mutations.
Utilized 19mer ASOs targeting JAK2 coding sequence
Performed qPCR and Western blot analyses on HEL and SET2 cell lines
Evaluated PBMCs from PV patients in methylcellulose cultures with ASO treatment
Demonstrated ~50% reduction of JAK2 transcript in HEL cells after ASO treatment
Observed ~70% decrease in JAK2 protein levels in ASO-treated cells
Noted a 35% reduction in phosphorylated STAT5 levels after treatment
Reduced erythroid colony formation in PV PBMCs post-ASO treatment

Cite This Study

Przychodzen et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d215 https://doi.org/10.1182/blood-2025-7283

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark